Ilika plc award share options under the long term incentive plan

Ilika plc

Ilika plc (LON:IKA), a pioneer in solid-state battery technology, has announced that on 7 February 2022 it granted nominal value options over 229,759 ordinary shares of 1p each in the Company to Executive Directors under the Long Term Incentive Plan 2018. Each award vests on the achievement of certain performance targets over a three-year period. The options granted represent in aggregate 0.15 per cent of the Company’s issued share capital.

In addition, on 7 February 2022, 20,000 nominal value options previously awarded under the Company’s bonus scheme have been exercised by Steve Boydell, CFO, and the Executive Directors sold 30,000 shares in aggregate, primarily to cover tax liabilities arising from options exercised under the Company’s bonus scheme in 2021 and 2022.

Details of grants issued under the Company’s Long Term Incentive Plan 2018, options exercised and Ordinary Shares sold by each Executive Director are set out in the tables below, together with the total number of Ordinary Shares each Executive Director holds under option and is interested in.

DirectorNumber of options grantedNumber of options exercisedTotal number of Options now heldPer cent. of issued share capital
Graeme Purdy153,5412,362,1131.50
Steve Boydell76,21820,000755,7230.48
DirectorOrdinary shares soldNumber of shares held post salePer cent. of issued share capital
Graeme Purdy15,000782,9270.50
Steve Boydell15,00058,3460.04

EMI option scheme

Following the vesting of options under Ilika’s EMI share option schemes, 52,500 options with an exercise price of 21p, together with 265,000 options with an exercise price of 18.2p, have been converted into Ordinary shares of 1p each. 

Accordingly, to satisfy options exercised under both the Company’s EMI share option schemes and bonus scheme, the Company has applied to the London Stock Exchange for 337,500 Ordinary Shares to be admitted to trading on AIM. It is expected that Admission will occur at 8.00am on 11 February 2022.

Total Voting Rights

Following Admission, the Ilika issued share capital will comprise 157,217,043 Ordinary Shares and may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure Guidance and Transparency Rules. The Company does not hold any shares in treasury. 

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:
Ilika plc reports impressive 2024 half-year results, advancing solid-state battery tech with Stereax and Goliath for MedTech and EV applications.
Ilika plc's CEO, Graeme Purdy, discusses the successful commissioning of Stereax batteries at Cirtec, product qualification, and future developments.
Ilika plc advances solid-state battery tech with Stereax® production starting in the US, marking a pivotal step towards commercial sales this year.
Ilika Plc CEO Graeme Purdy discusses Stereax battery production at Certec, marking a key milestone in solid-state tech and medtech applications.
Ilika plc begins process qualification for Stereax batteries at Cirtec Medical's facility, marking a key step in advanced solid state battery production.
Ilika plc appoints Cavendish Capital Markets as Nominated Adviser and Sole Broker, enhancing its solid-state battery technology ventures.

Search

Search